FDA permits marketing of first medical device for treatment of ADHD
(WorldNews Health)

SILVER SPRING, Md., April 19, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to12 years old who are not currently taking prescription ADHD medication and is the first non-drug treatment for ADHD granted marketing authorization by the FDA. `This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients through the use of mild nerve stimulation, a first of its kind,` said Carlos Peña, Ph.D., director of the...